Prior immune checkpoint inhibitor (ICI) therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry
Description
CONCLUSIONS: In this PSM analysis, prior ICI therapy did not worsen and potentially improved COVID-19-outcomes in patients with cancer.